GSK, Pfizer and RSV
RSV vaccines from Pfizer, GSK take another hit with new FDA warning mandate
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare neurological condition that can cause paralysis.
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...
Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its ...
From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...
The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
The stock's fall snapped a two-day winning streak.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback